Clinical trial
Ranibizumab Intravitreal Injections in Patients With Visual Impairment Due to…
NCT01535261 · Novartis Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT01535261 |
|---|---|
| Title | Ranibizumab Intravitreal Injections in Patients With Visual Impairment Due to Macular Edema Secondary to Central Retinal Vein Occlusion |
| Official title | A 24-month, Phase IIIb, Open-label, Single Arm, Multicenter Study Assessing the Efficacy and Safety of an Individualized, Stabilization-criteria-driven PRN Dosing Regimen With 0.5-mg Ranibizumab Intravitreal Injections Applied as Monotherapy in Patients With Visual Impairment Due to Macular Edema… |
| Acronym | CRYSTAL |
| Lead sponsor | Novartis Pharmaceuticals, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Macular Edema, Central Retinal Vein Occlusion |
| Intervention type | Drug |
| Interventions | Ranibizumab 0.5 mg/0.05 ml |
| Enrollment | 357 |
| Start date | Feb 1, 2012 |
| Primary completion | Mar 1, 2015 |
| Completion | Mar 1, 2015 |
| First posted | Feb 17, 2012 |
| Last update posted | Oct 27, 2016 |
| Countries | Australia, Austria, Canada, Czechia, Denmark, Greece, Hungary, Ireland, Italy, Netherlands, Poland, Portugal and 6 more |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: